



## Supplement

Figure 1. Flow diagram



Supplemental Figure 1 shows the flow diagram for inclusion of participants and tests in this analysis. Here, CDC assay indicates CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel and ThermoFisher assay indicates ThermoFisher TaqPath™ COVID-19 ComboKit. Participants were tested on one of these platforms based on testing availability at the enrolling site at the time of that participants' enrollment, and were only included in the analysis if all specimens they collected were tested using the same assay.

Figure 2. Order of dates of symptom onset and dates of first positive specimen among participants experiencing each symptom.



Supplemental Figure 2 shows the order of dates of symptom onset and dates of first positive specimen among participants experiencing each symptom. The fill of the bar indicates whether people with incident cases of SARS-CoV-2 first reported the symptom prior to testing positive (dark gray), the same day they tested positive (medium gray), or after testing positive (light gray)

during daily symptom diaries. The bars depict the proportion of people with incident cases of SARS-CoV-2 who ever experienced that symptom who fell into one of these three categories. The black numbers to the right of each bar indicate the denominator for these proportions (that is, the number of people with incident cases of SARS-CoV-2 who ever experienced each particular symptom).

Table 1. Experienced symptoms and adjusted associations with daily Ct values.

Symptom	Ever reported/asked	Symptomatic at end of follow-up*	Association with Ct value**	P value
Any	62/67	35	-1.6 [-2.3, -1.0]	p < 0.001
<b>Constitutional</b>				
Fatigue	52/67	19	-1.1 [-1.6, -0.6]	p < 0.001
Fever	33/67	5	-1.5 [-2.3, -0.8]	p < 0.001
Aches†	21/28	2	-1.3 [-2.1, -0.5]	p = 0.001
Chills†	13/28	1	-2.2 [-3.4, -1.0]	p < 0.001
<b>Gastrointestinal</b>				
Diarrhea†	10/28	0	-3.0 [-4.3, -1.7]	p < 0.001
Abdominal pain†	9/28	0	-0.1 [-1.5, 1.3]	p = 0.846
Vomiting†	2/28	0	-0.0 [-0.1, 0.1]	p = 0.928
<b>Lower respiratory</b>				
Cough	46/67	20	-1.0 [-1.5, -0.5]	p < 0.001
Chest tightness/pain	16/67	2	-2.3 [-3.4, -1.3]	p < 0.001
Shortness of breath	16/67	2	-1.6 [-2.8, -0.5]	p = 0.004
Wheezing	7/67	1	-2.2 [-3.5, -1.0]	p = 0.001
<b>Upper respiratory</b>				
Nasal congestion	49/67	23	-1.2 [-1.7, -0.7]	p < 0.001
Runny nose	45/67	15	-1.0 [-1.6, -0.5]	p < 0.001
Sore throat	40/67	7	-0.8 [-1.4, -0.2]	p = 0.008
<b>Neurologic</b>				
Headache†	48/61	13	-1.5 [-2.0, -1.0]	p < 0.001
Loss of taste or smell	29/67	15	0.2 [-0.5, 0.9]	p = 0.557

\* Indicates the number of people who were symptomatic at the end of follow-up. The median duration of follow-up after the first positive specimen was 10 days (range: 2, 12).

\*\* The association between symptom status and Ct values was determined by one generalized additive model per symptom, accounting for time since first testing positive, the SARS-CoV-2 test target, and the age of the case. Associations are in units of Ct values, so that negative estimates suggest that if a case reported experiencing that symptom on a particular day, the Ct values from the specimens collected that day would be lower.

†Some symptoms were assessed only at one site (Marshfield Clinic Research Institute but not Vanderbilt University Medical Center), or not assessed in children under the age of 5; see[15]

Table 2. Test characteristics among 67 incident cases

	Overall	Age 0-11	Age 12-17	Age 18-49	Age 50+
<b>CDC: N1 target</b>					
Participants (n)	30	6	5	14	5
Specimens (n)	214	37	26	117	34
Ct value, median [IQR]	28.1 [24.6, 32.9]	30.0 [26.9, 34.5]	28.3 [26.3, 32.4]	27.9 [24.1, 33.3]	27.3 [22.6, 30.3]
<b>CDC: N2 target</b>					
Participants (n)	30	6	5	14	5
Specimens (n)	214	37	26	117	34
Ct value, median [IQR]	28.6 [25.1, 33.8]	31.4 [27.6, 34.8]	28.5 [26.0, 32.5]	28.3 [24.5, 34.3]	26.9 [22.6, 31.2]
<b>ThermoFisher: N target</b>					
Participants (n)	37	12	6	13	6
Specimens (n)	329	86	59	117	67
Ct value, median [IQR]	22.9 [18.0, 26.9]	24.8 [21.7, 28.6]	25.3 [19.8, 29.3]	21.4 [16.5, 26.7]	19.4 [15.9, 23.9]
<b>ThermoFisher: ORF1ab target</b>					
Participants (n)	37	12	6	13	6
Specimens (n)	327	83	59	118	67
Ct value, median [IQR]	22.4 [17.3, 26.6]	23.9 [21.2, 27.6]	24.8 [18.8, 28.8]	20.6 [16.2, 26.3]	18.8 [15.3, 23.0]
<b>ThermoFisher: S target</b>					
Participants (n)	34	10	6	12	6
Specimens (n)	300	72	56	105	67
Ct value, median [IQR]	21.6 [17.0, 25.7]	23.3 [20.2, 27.4]	24.3 [18.8, 27.9]	19.6 [15.5, 24.2]	18.7 [15.5, 22.9]

Table 1 shows the number of participants and number of analyzed tests for each assay target, along with the median and IQR of Ct values from those tests.

Table 3. Additional demographic variables and association with cycle threshold values.

Predictor	Predictor level	Incident cases	Model-based association (base model)*	Model-based association (base model plus age)*
Vaccination	None	60	Reference	Reference
	Partial†	7	-1.8 [CI -2.6, -1.0] p < 0.0001	0.3 [CI -0.5, 1.1] p = 0.431
Conditions	None	54	Reference	Reference
	At least one	13	-1.5 [CI -2.2, -0.9] p < 0.0001	-0.7 [CI -1.3, -0.1] p = 0.019
Sex	Female	32	Reference	Reference
	Male	35	-0.9 [CI -1.5, -0.4] p = 0.001	-0.5 [CI -1.0, 0.0] p = 0.071

\*The base model was specified similar to model 1 in the primary methods: a generalized additive model predicting cycle threshold values with a random effect spline for repeated measurements within individuals, a smoothing spline for the number of days that elapsed since the first positive specimen, and controlling for the target of each assay. The model that adjusted for age included another predictor, categorical age (0-11, 12-17, 18-49, or 50+).

†Partial vaccination was defined as having received one dose of an mRNA vaccine prior to household exposure to SARS-CoV-2. No incident cases were fully vaccinated.